VYNE Therapeutics Q3 net loss narrows, strategic review ongoing
I'm PortAI, I can summarize articles.
VYNE Therapeutics reported a narrowed Q3 net loss of $7.28 million, with revenue of $169,000. The company is undergoing a strategic review to explore partnerships or mergers, aiming to maximize shareholder value. Cost reductions have been implemented to extend the cash runway into the first half of 2027. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $3.25, significantly above its recent closing price of $0.34.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments